MARKHAM, Ontario, Aug. 28, 2017 -- MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.
MedReleaf’s CEO, Neil Closner, is scheduled to present on Wednesday, September 6 at 3:30 p.m. Pacific time, with one-on-one meetings held throughout the conference.
The presentation will be webcast live and available for replay in the Investor Relations section of MedReleaf’s website at http://investors.medreleaf.com/ or on the Gateway Conference website at www.gateway-conference.com/presenters.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
Investor Contact: Dennis Fong, Investor Relations, [email protected], (416) 283-9930


Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



